DK2452281T3 - Fremgangsmåde til at forudsige virkningen af lægemidler i en patient - Google Patents
Fremgangsmåde til at forudsige virkningen af lægemidler i en patient Download PDFInfo
- Publication number
- DK2452281T3 DK2452281T3 DK10730780.3T DK10730780T DK2452281T3 DK 2452281 T3 DK2452281 T3 DK 2452281T3 DK 10730780 T DK10730780 T DK 10730780T DK 2452281 T3 DK2452281 T3 DK 2452281T3
- Authority
- DK
- Denmark
- Prior art keywords
- pharmaceuticals
- patient
- procedure
- preventing
- effect
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H70/00—ICT specially adapted for the handling or processing of medical references
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H70/00—ICT specially adapted for the handling or processing of medical references
- G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Primary Health Care (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Evolutionary Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Medicinal Chemistry (AREA)
- Theoretical Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Pathology (AREA)
- Databases & Information Systems (AREA)
- Data Mining & Analysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22379809P | 2009-07-08 | 2009-07-08 | |
| PCT/EP2010/059648 WO2011003911A1 (en) | 2009-07-08 | 2010-07-06 | Method for predicting efficacy of drugs in a patient |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2452281T3 true DK2452281T3 (da) | 2020-01-13 |
Family
ID=42790891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10730780.3T DK2452281T3 (da) | 2009-07-08 | 2010-07-06 | Fremgangsmåde til at forudsige virkningen af lægemidler i en patient |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10095829B2 (da) |
| EP (1) | EP2452281B1 (da) |
| JP (1) | JP5773998B2 (da) |
| CN (1) | CN102473202B (da) |
| AU (1) | AU2010270227B2 (da) |
| CA (1) | CA2767659C (da) |
| DK (1) | DK2452281T3 (da) |
| EA (1) | EA021945B1 (da) |
| ES (1) | ES2763899T3 (da) |
| IL (1) | IL217338A (da) |
| NZ (1) | NZ597655A (da) |
| SG (2) | SG177571A1 (da) |
| WO (1) | WO2011003911A1 (da) |
| ZA (1) | ZA201200872B (da) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8067178B2 (en) | 2008-03-14 | 2011-11-29 | Genomic Health, Inc. | Gene expression markers for prediction of patient response to chemotherapy |
| ES2925983T3 (es) | 2010-07-27 | 2022-10-20 | Genomic Health Inc | Método para usar la expresión génica para determinar el pronóstico del cáncer de próstata |
| EP2601633A4 (en) * | 2010-08-06 | 2016-11-30 | Cardiomems Inc | SYSTEMS AND METHODS OF USE OF PHYSIOLOGICAL INFORMATION |
| SG10201912312YA (en) | 2012-01-31 | 2020-02-27 | Genomic Health Inc | Gene expression profile algorithm and test for determining prognosis of prostate cancer |
| RU2509808C1 (ru) * | 2012-10-30 | 2014-03-20 | Федеральное государственное бюджетное учреждение науки Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук (ИХБФМ СО РАН) | СПОСОБ ОПРЕДЕЛЕНИЯ ЧУВСТВИТЕЛЬНОСТИ КЛЕТОК НЕМЕЛКОКЛЕТОЧНОГО РАКА ЛЕГКИХ К ДЕЙСТВИЮ ПРЕПАРАТОВ, РЕАКТИВИРУЮЩИХ БЕЛОК р53 |
| US10709341B2 (en) | 2012-11-21 | 2020-07-14 | St. Jude Medical Luxembourg Holdings II S.a.r.l. | Devices, systems, and methods for pulmonary arterial hypertension (PAH) assessment and treatment |
| US10262112B2 (en) * | 2013-02-04 | 2019-04-16 | Precera Bioscience, Inc. | Prescription decision support system and method using comprehensive multiplex drug monitoring |
| WO2014137705A1 (en) * | 2013-03-05 | 2014-09-12 | The Board Of Trustees Of The Leland Stanford Junior University | Assessing risk for encephalopathy induced by 5-fluorouracil or capecitabine |
| WO2014145712A1 (en) | 2013-03-15 | 2014-09-18 | Cardiomems, Inc. | Methods for the treatment of cardiovascular conditions |
| RU2528247C2 (ru) * | 2013-05-07 | 2014-09-10 | Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) | Способ оценки чувствительности клеток рака легкого к доксорубицину на основании уровней экспрессии маркерных генов и набор для его осуществления |
| ES2855698T3 (es) * | 2013-06-20 | 2021-09-24 | Taiho Pharmaceutical Co Ltd | Método para predecir la eficacia terapéutica del inhibidor de PI3K/AKT/mTOR basándose en la expresión de PHLDA1 o PIK3C2B |
| EP3495504B1 (en) * | 2013-08-19 | 2020-10-07 | Cipherome, Inc. | Method and system for selecting drug on basis of individual protein damage information for preventing side effects of drug |
| EP2881472A1 (en) | 2013-12-09 | 2015-06-10 | Université Pierre et Marie Curie (Paris 6) | A method of predicting a response to an anti-tumor treatment |
| SG11201607918TA (en) * | 2014-04-24 | 2016-11-29 | Pfizer | Cancer treatment |
| EP3240911B1 (en) * | 2014-12-31 | 2020-08-26 | Guardant Health, Inc. | Detection and treatment of disease exhibiting disease cell heterogeneity and systems and methods for communicating test results |
| US11195594B2 (en) | 2015-02-17 | 2021-12-07 | Cipherome, Inc. | Method for selecting anticancer agent based on protein damage information of individual to prevent anticancer agent side effects |
| WO2018078142A1 (en) * | 2016-10-28 | 2018-05-03 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Means and methods for determining efficacy of fluorouracil (5-fu) in colorectal cancer (crc) therapy |
| CN113684275B (zh) * | 2017-06-22 | 2024-02-27 | 北海康成（北京）医药科技有限公司 | 预测食管癌对抗erbb3抗体治疗的应答的方法和试剂盒 |
| US10636512B2 (en) | 2017-07-14 | 2020-04-28 | Cofactor Genomics, Inc. | Immuno-oncology applications using next generation sequencing |
| RU2670656C9 (ru) * | 2017-08-30 | 2018-12-12 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ прогнозирования роста опухоли в эксперименте |
| CN108053887A (zh) * | 2017-11-02 | 2018-05-18 | 杭州英放生物科技有限公司 | 一种实体瘤疗效评估方法、电子设备、存储介质、*** |
| RU2741703C1 (ru) * | 2018-03-01 | 2021-01-28 | Общество с ограниченной ответственностью «Онкобокс» | Платформа анализа генетической информации oncobox |
| US11424011B2 (en) * | 2018-12-10 | 2022-08-23 | International Business Machines Corporation | Analyzing knowledge graphs with unbounded insight generation |
| US20200222538A1 (en) * | 2019-01-15 | 2020-07-16 | International Business Machines Corporation | Automated techniques for identifying optimal combinations of drugs |
| CN110241215B (zh) * | 2019-07-03 | 2020-05-19 | 上海润安医学科技有限公司 | 一种用于检测甲状腺结节良恶性相关基因变异的引物及试剂盒 |
| US11373281B1 (en) * | 2021-02-23 | 2022-06-28 | Qualcomm Incorporated | Techniques for anchor frame switching |
| JP2024509887A (ja) * | 2021-03-09 | 2024-03-05 | ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド | Ｅｐ３００分解剤および神経芽細胞腫におけるその使用 |
| KR102421469B1 (ko) * | 2021-10-06 | 2022-07-18 | (주)이노베이션바이오 | 암 진단용 바이오마커 및 이의 용도 |
| WO2023109876A1 (en) * | 2021-12-16 | 2023-06-22 | Edigene Therapeutics (Beijing) Inc. | Biomarkers for colorectal cancer treatment |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002510817A (ja) * | 1998-04-03 | 2002-04-09 | トライアングル・ファーマシューティカルズ，インコーポレイテッド | 治療処方計画の選択をガイドするためのシステム、方法及びコンピュータ・プログラム製品 |
| JP2006271385A (ja) * | 2001-03-14 | 2006-10-12 | Dna Chip Research Inc | 大腸癌の予測方法 |
| JP4222835B2 (ja) | 2001-03-14 | 2009-02-12 | 株式会社Ｄｎａチップ研究所 | 癌の予測方法 |
| US20060275747A1 (en) | 2001-12-07 | 2006-12-07 | Hardy Stephen F | Endogenous retrovirus up-regulated in prostate cancer |
| JP4646315B2 (ja) * | 2001-12-07 | 2011-03-09 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | 前立腺癌においてアップレギュレートされた内因性レトロウイルス |
| US20050118600A1 (en) | 2002-03-13 | 2005-06-02 | Yuko Aoki | Method for selecting drug sensitivity-determining factors and method for predicting drug sensitivity using the selected factors |
| JP2005038256A (ja) * | 2003-07-16 | 2005-02-10 | Jgs:Kk | 有効因子情報選択装置、有効因子情報選択方法、プログラム、および、記録媒体 |
| US8000982B2 (en) * | 2004-02-17 | 2011-08-16 | Body Bio, Inc. | Network and methods for integrating individualized clinical test results and nutritional treatment |
| US7693857B2 (en) * | 2005-11-17 | 2010-04-06 | International Business Machines Corporation | Clinical genomics merged repository and partial episode support with support abstract and semantic meaning preserving data sniffers |
| JP2009517186A (ja) | 2005-11-29 | 2009-04-30 | チルドレンズ ホスピタル メディカル センター | 薬物選択及び投薬の最適化及び個別化 |
| US20070198653A1 (en) * | 2005-12-30 | 2007-08-23 | Kurt Jarnagin | Systems and methods for remote computer-based analysis of user-provided chemogenomic data |
| US7788259B2 (en) * | 2006-07-21 | 2010-08-31 | Microsoft Corporation | Locating, viewing and interacting with information sources |
| US20080118576A1 (en) | 2006-08-28 | 2008-05-22 | Dan Theodorescu | Prediction of an agent's or agents' activity across different cells and tissue types |
-
2010
- 2010-07-06 EP EP10730780.3A patent/EP2452281B1/en active Active
- 2010-07-06 AU AU2010270227A patent/AU2010270227B2/en active Active
- 2010-07-06 ES ES10730780T patent/ES2763899T3/es active Active
- 2010-07-06 EA EA201200101A patent/EA021945B1/ru not_active IP Right Cessation
- 2010-07-06 DK DK10730780.3T patent/DK2452281T3/da active
- 2010-07-06 SG SG2012001384A patent/SG177571A1/en unknown
- 2010-07-06 NZ NZ597655A patent/NZ597655A/xx unknown
- 2010-07-06 US US13/382,585 patent/US10095829B2/en active Active
- 2010-07-06 WO PCT/EP2010/059648 patent/WO2011003911A1/en active Application Filing
- 2010-07-06 SG SG10201403896XA patent/SG10201403896XA/en unknown
- 2010-07-06 CN CN201080030902.XA patent/CN102473202B/zh active Active
- 2010-07-06 CA CA2767659A patent/CA2767659C/en active Active
- 2010-07-06 JP JP2012518969A patent/JP5773998B2/ja active Active
-
2012
- 2012-01-03 IL IL217338A patent/IL217338A/en active IP Right Grant
- 2012-02-06 ZA ZA2012/00872A patent/ZA201200872B/en unknown
-
2018
- 2018-09-10 US US16/125,803 patent/US20190005190A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NZ597655A (en) | 2013-05-31 |
| JP5773998B2 (ja) | 2015-09-02 |
| ZA201200872B (en) | 2012-10-31 |
| SG10201403896XA (en) | 2014-10-30 |
| EP2452281A1 (en) | 2012-05-16 |
| US20120136583A1 (en) | 2012-05-31 |
| CN102473202A (zh) | 2012-05-23 |
| US10095829B2 (en) | 2018-10-09 |
| AU2010270227B2 (en) | 2015-01-22 |
| JP2012533103A (ja) | 2012-12-20 |
| EP2452281B1 (en) | 2019-10-02 |
| ES2763899T3 (es) | 2020-06-01 |
| EA021945B1 (ru) | 2015-10-30 |
| IL217338A0 (en) | 2012-02-29 |
| US20190005190A1 (en) | 2019-01-03 |
| CN102473202B (zh) | 2015-11-25 |
| CA2767659C (en) | 2020-10-20 |
| SG177571A1 (en) | 2012-03-29 |
| AU2010270227A1 (en) | 2012-02-09 |
| EA201200101A1 (ru) | 2012-08-30 |
| IL217338A (en) | 2017-12-31 |
| CA2767659A1 (en) | 2011-01-13 |
| WO2011003911A1 (en) | 2011-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2452281T3 (da) | Fremgangsmåde til at forudsige virkningen af lægemidler i en patient | |
| DK3192520T3 (da) | Terapeutiske midler til reducering af niveauerne af parathyreoideahormon | |
| DK2462116T3 (da) | Fremgangsmåde til fremstillingen af farmaceutisk aktive forbindelser | |
| DK2389918T3 (da) | Anordning til indgivelse af væske i næse-øre-hals-området | |
| DK2498771T3 (da) | Anvendelse af bethanechol til behandling af xerostomi | |
| BRPI0920521A2 (pt) | combinação farmacêutica | |
| SMT201400069B (it) | Formulazione farmaceutica | |
| BRPI0914984A2 (pt) | auto-injetor reutilizável | |
| DK3097925T3 (da) | Farmaceutisk sammensætning | |
| DK2173407T3 (da) | Anordning til indgivelse af lægemiddel | |
| BRPI0915879A2 (pt) | dispositivos médicos temporariamente posicionáveis | |
| BRPI0914981A2 (pt) | autoinjetor reutilizável | |
| DK2482899T3 (da) | Konstruktion til indretning til indgivelse af lægemiddel | |
| DK2381986T3 (da) | Lægemiddeladministrationsanordning | |
| DK2451482T3 (da) | Kombinationsterapi til behandlingen af diabetes | |
| DK2408807T3 (da) | Fremgangsmåde til terapeutisk anvendelse | |
| DK3005986T3 (da) | Infusion af lægemidler | |
| NL301214I2 (nl) | Lasmiditan en farmaceutisch aanvaardbare zouten daarvan | |
| BRPI0922653A2 (pt) | preparação farmacêutica | |
| BR112012003149A2 (pt) | composição farmacêutica | |
| BRPI1013722A2 (pt) | seringa dental | |
| DK2468138T3 (da) | Tværstiver til en reol | |
| DK2462108T3 (da) | Fremgangsmåde til fremstilling af pyrazolcarboxylsyreamider | |
| DK2420219T3 (da) | Indgivelsesport | |
| DK2568805T3 (da) | En medicinsk væske, en fremgangsmåde til behandling og anvendelse af væsken |